VRTX250502C345000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Express News | CNBC Halftime Report Final Trades: Berkshire Hathaway - B Shares, Vertex Pharmaceuticals, S&P Global, CME Group
Earnings Preview: VRTX to Report Financial Results Post-market on May 05
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals Hits 4-week High
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
Express News | The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion For Vertex Pharmaceuticals' Alyftrek (Deutivacaftor/Tezacaftor/Vanzacaftor) For Cystic Fibrosis Patients Aged 6 Years And Older Who Have At Least...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Erasca (ERAS)
Vertex Receives CHMP Positive Opinion for ALYFTREK, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis
Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street
US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies
Evercore Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $510
Evercore ISI Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Stock (VRTX) Trending as Q1 Earnings Approach
New Analyst Forecast: $VRTX Given $535.0 Price Target
UBS Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $583
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts
Cantor Fitzgerald Assumes Vertex Pharmaceuticals at Overweight, Announces Price Target of $535
Vertex Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Initiates Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $535